Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.
PURPOSE: This phase II trial is studying how well bortezomib works in treating patients with
relapsed or refractory cutaneous T-cell lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborators:
Millennium Pharmaceuticals, Inc. National Cancer Institute (NCI)